马应龙品牌怎么样 申请店铺

马应龙（600993.SH）是一家经商务部首批认定的中华老字号企业，创始于公元1582年。长久以来，马应龙致力于医药产业的专业化发展，坚持以肛肠治痔领域为核心定位，经过多年持续快速健康发展，如今已成长为一家涉足于药品制造、药品研发、药品批发零售、连锁医院等多个领域的专业化多功能国际化的上市公司。

公司生产功能齐全，可生产剂型超过30种，可供生产的国药准字号药品超过300种，拥有独家品种20多个，共有18个国药准字号品种入选《国家基本药物目录》，37个品种入选《国家医保目录》，其中马应龙麝香痔疮膏、麝香痔疮栓、龙珠软膏、马应龙八宝眼膏为公司独家产品。生产设施先进，主要品种生产流水线及配套设施的技术水平已处于国内领先水平。

公司围绕核心定位，开展系列化药品研发。目前，在销肛肠治痔系列产品达到7个品种，在研治痔项目3个，涵盖膏剂、栓剂、西药口服片剂、中药口服片剂、洗剂、胶囊剂、乳膏凝胶剂、气雾剂、散剂、颗粒剂等多种剂型，立项在研肛肠治痔类品种6种，其他在研项目8个。公司还开发出系列化眼部护理药妆产品，积极进军药妆市场，目前在研项目11个。

公司现有一支人员配备齐整、结构合理、优势互补的技术团队，并有一批从事药物合成、中药提取、制药工程和药理毒理及临床试验评价等方面研究的学科带头人。公司与北京大学药学院、中国药科大学等多家科研机构建立了长期的战略合作关系。经国家人事部核准公司与北京大学共同组建了博士后工作站。2009年，马应龙药业集团股份有限公司技术中心被国家发改委、科技部等五部委认定为国家级企业技术中心，马应龙创新药物研发团队被湖北省委组织部认定为首批“湖北省重点产业创新团队”。

根据国家药监局南方医药经济研究所统计数据，马应龙在痔疮药品零售市场的份额超过40%，成为治痔领域的第一品牌。

公司建立了较为完善的营销管理体系和覆盖全国的营销网络平台，与国内医药流通领域位居前列的300多家企业均建立了长期合作关系，产品远销东南亚及欧美大陆。

马应龙及旗下子公司分别通过了国家药监局GMP、GSP质量管理规范体系认证，获得国际权威机构SGS颁发的环境管理体系ISO14000和职业安全与健康管理体系OHSAS18000的认证，在医药行业内率先实现了“三认证”。在世界品牌实验室、世界经理人周刊联合评估的2010年“中国最具价值品牌500强”排行榜中，马应龙名列第210位，品牌价值达到了43.21亿元。2005年，马应龙在人民日报、中国企业文化促进会、中国质量与品牌杂志社等六家公共传媒的联合评选中荣获“中国痔疮药物最具影响力品牌”。2006年，马应龙荣获国家工商总局认定的“中国驰名商标”，成为中国治痔领域唯一的“中国驰名商标”。2009年，马应龙被中国非处方药物协会评选为“中国非处方药品牌企业十五强”。

公司股票于2004年在上海证券交易所上市，由此获得了持续融资的通道和规范营运的平台。公司股票先后被上海证券交易所、中国证券指数公司选定为中国上市公司治理指数样本股及上证社会责任指数样本股。公司先后获评“优秀董事会奖”、“最重股东权益上市公司”，标志着公司治理水平获得社会公众、证券机构及专家的高度认可。

传承四百多年的历史文化，公司逐步形成了具有马应龙特色的企业文化体系。公司秉承“为顾客创造健康，为股东创造财富，为员工创造机会，为社会创造效益”的经营宗旨，倡导“以真修心，以勤修为”的哲学观，倡导“稳健经营、协调发展”的经营观，倡导“资源增值”的价值观，弘扬“龙马精神”的企业精神。马应龙将以实现中药现代化为己任，在品牌经营战略的指引下与时俱进，继往开来。

Ma Yinglong (600993. SH) is one of the first batch of Chinese time-honored enterprises recognized by the Ministry of Commerce. It was founded in 1582 ad. For a long time, Ma Yinglong has been committed to the professional development of the pharmaceutical industry, adhere to the core positioning in the field of anorectal hemorrhoids treatment. After years of sustained, rapid and healthy development, he has now grown into a professional and multi-functional international listed company involved in many fields, such as drug manufacturing, drug research and development, drug wholesale and retail, chain hospitals, etc. The company has complete production functions, can produce more than 30 dosage forms, can produce more than 300 kinds of Guoyao Zhun brand drugs, has more than 20 exclusive varieties, a total of 18 Guoyao Zhun brand varieties have been selected into the national basic drug catalog, 37 varieties have been selected into the national medical insurance catalog, among which the company is Ma Yinglong musk Hemorrhoid Cream, musk hemorrhoid suppository, Longzhu ointment and Ma Yinglong Babao eye cream Exclusive products. The production facilities are advanced, and the technical level of production lines and supporting facilities of main varieties has been at the leading level in China. Focusing on the core positioning, the company carried out a series of drug research and development. At present, there are 7 kinds of products in the treatment of hemorrhoids in anus and intestine, and 3 items in the research and treatment of hemorrhoids. They include 3 kinds of dosage forms, such as ointment, suppository, western medicine oral tablet, Chinese medicine oral tablet, lotion, capsule, cream gel, aerosol, powder, granule, etc., and are set up for 6 kinds of hemorrhoids and 8 other research projects. The company has also developed a series of eye care cosmetics products and actively entered the cosmetics market. At present, there are 11 projects under research. At present, the company has a technical team with complete personnel, reasonable structure and complementary advantages, as well as a group of discipline leaders engaged in drug synthesis, extraction of traditional Chinese medicine, pharmaceutical engineering, pharmacology and toxicology and clinical trial evaluation. The company has established a long-term strategic cooperation relationship with many scientific research institutions, such as the school of pharmacy of Peking University and China Pharmaceutical University. With the approval of the Ministry of personnel of the people's Republic of China, the company and Peking University jointly set up a postdoctoral workstation. In 2009, the technology center of Ma Yinglong Pharmaceutical Group Co., Ltd. was recognized as a national enterprise technology center by five ministries and commissions including the national development and Reform Commission and the Ministry of science and technology, and the R & D team of Ma Yinglong innovative drugs was recognized as the first batch of "Hubei key industry innovation team" by the Organization Department of Hubei Provincial Committee. According to the statistics of Nanfang pharmaceutical Economic Research Institute of the State Food and drug administration, Ma Yinglong has more than 40% of the retail market of hemorrhoids, becoming the first brand in the field of hemorrhoids treatment. The company has established a relatively perfect marketing management system and a nationwide marketing network platform, and has established long-term cooperative relations with more than 300 domestic pharmaceutical circulation enterprises, whose products are exported to Southeast Asia, Europe and the United States. Ma Yinglong and its subsidiaries have respectively passed the GMP and GSP quality management standard system certification issued by the State Food and drug administration, obtained the certification of ISO14000 environmental management system and OHSAS18000 occupational safety and health management system issued by the international authoritative agency SGS, and took the lead in realizing the "three certifications" in the pharmaceutical industry. Ma Yinglong ranked No. 210 in the "top 500 most valuable brands in China" list jointly evaluated by world brand laboratory and World Manager weekly, with the brand value reaching 4.321 billion yuan. In 2005, Ma Yinglong won the title of "the most influential brand of Chinese hemorrhoids" in the joint selection of six public media, including people's daily, China Association for the promotion of corporate culture, China Quality and brand magazine. In 2006, Ma Yinglong won the "China famous trademark" recognized by the State Administration for Industry and commerce, and became the only "China famous trademark" in the field of hemorrhoids treatment in China. In 2009, Ma Yinglong was selected as "top 15 brand enterprises of Chinese OTC" by China OTC Association. The company's stock was listed on the Shanghai Stock Exchange in 2004, thus obtaining a channel for continuous financing and a platform for standardized operation. The company's shares have been selected by Shanghai Stock Exchange and China Securities Index Company as sample shares of China's listed corporate governance index and Shanghai Stock social responsibility index. The company has been awarded "excellent board Award" and "listed company with the most shareholder's rights and interests", which indicates that the level of corporate governance has been highly recognized by the public, securities institutions and experts. Inheriting more than 400 years of history and culture, the company has gradually formed a corporate culture system with Ma Yinglong's characteristics. The company adheres to the business tenet of "creating health for customers, creating wealth for shareholders, creating opportunities for employees and creating benefits for the society", advocates the philosophy of "cultivating the heart with sincerity, cultivating the mind with diligence", advocates the business concept of "stable operation and coordinated development", advocates the value concept of "resource added value", and promotes the enterprise spirit of "Longma spirit". Ma Yinglong will take the modernization of traditional Chinese medicine as his duty, keep pace with the times and carry forward the past and open up the future under the guidance of brand management strategy.

本文链接： https://brand.waitui.com/4ad730f44.html 联系电话：027-87291611